Home/Filings/4/0001415889-22-008006
4//SEC Filing

Hindman Andrew A. 4

Accession 0001415889-22-008006

CIK 0001583107other

Filed

Jul 26, 8:00 PM ET

Accepted

Jul 27, 6:56 PM ET

Size

5.1 KB

Accession

0001415889-22-008006

Insider Transaction Report

Form 4
Period: 2022-07-25
Hindman Andrew A.
SVP, Chief Financial Officer
Transactions
  • Award

    Ordinary Shares

    2022-07-25+20,000499,183 total
Footnotes (1)
  • [F1]On July 1, 2019, the reporting person was granted a performance stock unit award that vests based on the achievement of certain performance conditions over a three-year timeframe from 2019 through June 30, 2022 and continued employment. On June 30 2022, the performance conditions applicable to 20,000 shares were achieved and such shares will vest on August 20, 2023, subject to the reporting person's continued service.

Issuer

Theravance Biopharma, Inc.

CIK 0001583107

Entity typeother

Related Parties

1
  • filerCIK 0001607965

Filing Metadata

Form type
4
Filed
Jul 26, 8:00 PM ET
Accepted
Jul 27, 6:56 PM ET
Size
5.1 KB